Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 7;58(12):2009-2016.
doi: 10.1515/cclm-2020-1414.

IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Simon Thompson  1 , Mary Kathryn Bohn  2 , Nicasio Mancini  3 , Tze Ping Loh  4 , Cheng-Bin Wang  5 , Matthias Grimmler  6 , Kwok-Yung Yuen  7 , Robert Mueller  8 , David Koch  9 , Sunil Sethi  4 , William D Rawlinson  10 , Massimo Clementi  3 , Rajiv Erasmus  11 , Marc Leportier  12 , Gye Cheol Kwon  13 , María Elizabeth Menezes  14 , Maria-Magdalena Patru  15 , Maurizio Gramegna  16 , Krishna Singh  17 , Osama Najjar  18 , Maurizio Ferrari  3 , Giuseppe Lippi  19 , Khosrow Adeli  2 , Andrea R Horvath  20   1 ; IFCC Taskforce on COVID-19  20
Affiliations
Free article

IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Simon Thompson et al. Clin Chem Lab Med. .
Free article

Abstract

Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

Keywords: COVID-19; SARS-CoV-2; biochemistry; hematology.

PubMed Disclaimer

References

    1. Singh, A, Sood, N, Narang, V, Goyal, A. Morphology of COVID-19-affected cells in peripheral blood film. BMJ Case Rep 2020;13: e236117. https://doi.org/10.1136/bcr-2020-236117.
    1. Huang, I, Pranata, R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J. Intensive Care 2020; 8: 36. https://doi.org/10.1186/s40560-020-00453-4.
    1. Henry, BM, De Oliveira, MHS, Benoit, S, Plebani, M, Lippi, G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020; 58: 1021–8. https://doi.org/10.1515/cclm-2020-0369.
    1. Zhang, J, Dong, X, Cao, Y, Yuan, Y, Yang, Y, Yan, Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur J Allergy Clin Immunol 2020; 75: 1730–41. https://doi.org/10.1111/all.14238.
    1. Bao, J, Li, C, Zhang, K, Kang, H, Chen, W, Gu, B. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta 2020; 509: 180–94. https://doi.org/10.1016/j.cca.2020.06.009.

LinkOut - more resources